




Figure 1




Figure 2




Figure 3



Figure 4A




Figure 4B

- de-XTENylated bispecific (unmasked, activated)
- XTENylated bispecific (masked)




Figure 5A

- de-XTENylated bispecific (unmasked, activated)
- XTENylated bispecific (masked)

BT-474




Figure 5B

- de-XTENylated bispecific (unmasked, activated)
- XTENylated bispecific (masked)




Figure 6A




Figure 6B

- ◆ de-XTENylated bispecific (unmasked, activated)
- XTENylated bispecific (masked)

MDA-MB-453




Figure 6C




Figure 7A




Figure 7B




Figure 7C




Figure 7D

Single dose i.v. of XTENylated
(masked) bispecific (25 mpk) to:

- female monkey
- male monkey




Figure 8





Figure 9A



Negligible levels of AMX-818(PAT): 0.06-0.1%

Figure 9B

HER2-XPAT MTD is 42 mg/kg in Cynos




Figure 10A

HER2-PAT MTD is 0.2 mg/kg/D in Cynos




Figure 10B

Plasma concentrations in Cynomolgus Monkeys




Figure 10C




Figure 11A




Figure 11B




Figure 11C




Figure 11D




Figure 11E




Figure 12




Figure 13A




Figure 13B




Figure 14A




Figure 14B




Figure 14C

Median : Comp-FL4-A		
	IsoType	21.7
	0nM	132
	AMX818 0.6nM	127
	818-PAT 0.62nM	4301
	AMX818 600nM	3659




Figure 14D




Figure 15A




Figure 15B




Figure 15C




Figure 16A





Figure 13

On Average, 20% of XPAT in
Tumor Activated by Day 2



N=31 mice across 9 tumor types
including CRC, breast, gastric

FIGURE 16C